https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-75262003000500009
COLITIS ULCEROSA ASOCIADA AL EMBARAZO

 

INTRODUCCION  

La enfermedad inflamatoria intestinal (Colitis          ulcerosa, enfermedad de Cron se debe al resultado de una inapropiada activación          del sistema inmune de la pared intestinal. No existen nuevas luces sobre          su patogénesis, y tampoco se ha faci 

La evidencia acumulativa sugiere que la          flora luminal es un requisito, y quizás un factor central en el          desarrollo de enfermedad inflamatoria intestinal (12,          13). La activación del sistema inmune central          está eventualmente acompañado por la producción de          una amplia variedad de mediadores no específicos de la inflamación.          Estos incluyen muchas otras citoquinas, y factores de crecimiento así          como metabolitos del ácido araquidónico, y metabolitos reactivos          del oxígeno (14, 15). Estos          mediadores mantienen el proceso inflamatorio y desencadenan la destrucción          tisular, lo cual eventualmente se manifiesta clínicamente como          enfermedad (16, 17). 

El tratamiento se debe asociar a un adecuado          diagnóstico. El diagnóstico de enfermedad inflamatoria intestinal          depende de la historia clínica, hallazgos al examen físico,          hechos endoscópicos, radiológicos e histológicos,          así como el resultado de test de laboratorio de rutina (Tabla I).          Típicamente, estos hechos permiten un diagnósticos certero          de enfermedad inflamatoria intestinal y permite hacer la distinción          entre colitis ulcerosa y enfermedad de Con (18-21).          

Existen pocos reportes acerca de la enfermedad          inflamatoria intestinal, y la colitis ulcerosa en particular con respecto          a su asociación con el embarazo. Basados en un caso de esta condición          que fue manejado en nuestro servicio, analizamos y discutimos la literatura          internacional. 

CASO CLINICO 

Primera hospitalización 20/11/2002 

Paciente de 26 años, cursando embarazo          de 20+3 semanas por FUR y Eco concordantes y con diagnóstico de          colitis ulcerosa diagnosticada el año 1999 (colonoscopia y biopsia          confirmatoria), actualmente sin tratamiento, con hematoquezia desde hace          1 semana, color rojo rutilante, de moderada frecuencia y con una frecuencia          aproximada de 10 veces/día, asociado a dolor abdominal cólico,          además de baja de peso de          3 kilos en este tiempo, sin otra sintomatología. Ingresa por reactivación          de cuadro de base. Hábitos: fumadora. Antecedentes gíneco-obstétricos:          Menarquia: 12 años. Ritmo menstrual: V/30. FUR: 28/6/2002. MAC:          no refiere. G2P1A1: (Aborto espontáneo 1996 aproximadamente 10          semanas. Parto vaginal 1998, peso RN: 3.350 g).  

Paciente comenzó tratamiento con          azulfidina 50 mg c/8, prednisona 30 mg/día y ácido fólico          2 mg/día. 

Ecografía realizada mostró:          feto único vivo, cefálico, LCF (+), LA normal, placenta          anterior G1 y embarazo de 20+4 semanas por biometría fetal. 

En los exámenes destaca glóbulos          blancos 8.900, hb, 12,4, HTO 37%, PLT 193000, VHS 40, PCR 17. 

Paciente evolucionó favorablemente          a tratamiento médico, presentando deposiciones normales por lo          que es dada de alta, a los 5 días de su ingreso. 

Segunda hospitalización 21/2/2003 

Ingresa paciente con embarazo de 34+4,          debido a que ecografía mostró un feto creciendo bajo el          percentil 10 con Doppler normal, se hospitaliza para ver vía de          parto. En esta oportunidad con enfermedad de base inactiva. 

Durante su hospitalización se realizaron          3 ecografías que mostraron un feto creciendo bajo el percentil          10, con Doppler de la arteria uterina y cerebral media normal, sin evidencia          de otras alteraciones. 

Exámenes de laboratorio generales          dentro de parámetros normales. 

El día 2/3/2003 presenta un RBNS          no reactivo, con 2 episodios de bradicardia, además madre relata          hipomotilidad fetal motivo por el cual se programa cesárea electiva          (embarazo 35+5 semanas). En el parto se destaca: Placenta 280 gramos;          Cordón 45 cm; LA con meconio espeso; Sexo masculino; Peso 1540          g; Talla 42 cm; CC 30 cm; Apgar 8-8; Edad por examen físico 36          semanas; RN se traslada a UCI neonatal. 

DISCUSION 

Un manejo agresivo farmacoterapéutico,          y el uso de medidas quirúrgicas están frecuentemente contraindicadas          en el tratamiento de la colitis ulcerosa en el embarazo. Sin embargo,          en aquellas pacientes operadas, por ejemplo de colostomía parcial,          no se ha observado una disminución o alteración          de los resultados perinatal. Nuestra paciente había sido sometida          a una colostomía parcial antes de este embarazo.  

Los agentes derivados del 5 aminosalicilato          se han mantenido como tratamiento eficaz en pacientes con colitis ulcerosa          moderada desde el reconocimiento de la eficacia terapéutica del          agente pretotípico sulfazalasina (22-28).          Está determinado que la colitis ulcerosa no disminuye la fertilidad          en las mujeres en las cuales ingieren Salazosulfapyridina. El embarazo          debe ser planificado durante el período de remisión. Esta          paciente se manejaba con sulfasalazina, pero lamentablemente presentó          una exacerbación de su cuadro durante el embarazo. Los corticoides          han sido comúnmente usados cuando estos compuestos son inadecuados          o insuficientes. Ellos presumiblemente actúan a través de          las mismas propiedades funcionales referentes a otros procesos inflamatorios,          pero cual de ellos es especialmente importante en la enfermedad inflamatoria          intestinal no ha sido determinado, de hecho en nuestra paciente se realizó          un manejo combinado con sulfasalazina y corticoides con buenos resultados.          Especialmente en el período de desarrollo embrional, el uso de          antibióticos, drogas antiinflamatorias, quimioterápicos          y ACTH es considerada cuestionable, nuestra paciente recibió estos          fármacos al llegar a nuestro servicio. Un régimen terapéutico          conservador, el cual ha sido usado exitosamente en más de 80 pacientes          con enfermedad inflamatoria intestinal, es una combinación de terapias          que involucran la alimentación parenteral, comida que pueda ser          absorbida por las paredes intestinales, y farmacoterapia adaptativa (29).          

No existe evidencia que el aborto provocado          posea un efecto benéfico en el curso de la colitis ulcerosa. Los          embarazos sucesivos en la misma paciente con colitis ulcerosa coexistente          deben ser analizados individualmente. La cesárea será realizada          por indicaciones obstétricas solamente como fue el caso de nuestra          paciente. Es importante vigilar la colitis ulcerosa durante el primer          trimestre y el puerperio, así como una rigurosa supervisión          ginecológica durante el tercer mes del embarazo (30).          

El manejo multidiciplinario de esta paciente          permitió tener un buen resultado perinatal, sin compromiso materno.          

BIBLIOGRAFIA 

1. Cariappa A, Sands B,          Forcione D, Finkelstein D, Podolsky DK, Pillai S: Analysis of MHC class          II DP, DQ and DR alleles in Crohn's          disease. Gut 1998; 43: 210-5.          [ Links ] 2. Satsangi J, Welsh KI,          Bunce M et al: Contribution of genes of the major histocompatibility          complex to susceptibility and disease phenotype in inflammatory bowel          disease. Lancet 1996; 347: 1212-7.         [ Links ] 3. Negoro K, Kinouchi          Y, Hiwatashi N et al: Crohn's disease is associated with novel          polymorphisms in the 5-flanking region of the tumor necrosis factor gene.          Gastroenterology 1999; 117: 1062-8.         [ Links ] 4. Satsangi J, Parkes          M, Louis E et al: Two stage genome-wide search in inflammatory          bowel disease provides evidence for susceptibility loci on chromosomes          3, 7 and 12. Nat Genet 1996; 14: 199-202.         [ Links ] 5. Ma Y, Ohmen JD, Li          Z et al: A genome-wide search identifies potential new susceptibility          loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-8.         [ Links ] 6. Brant SR, Fu Y, Fields          CT et al: American families with Crohn's disease have strong evidence          for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998;          115: 1056-61.         [ Links ] 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 2. Satsangi J, Welsh KI,          Bunce M et al: Contribution of genes of the major histocompatibility          complex to susceptibility and disease phenotype in inflammatory bowel          disease. Lancet 1996; 347: 1212-7.         [ Links ] 3. Negoro K, Kinouchi          Y, Hiwatashi N et al: Crohn's disease is associated with novel          polymorphisms in the 5-flanking region of the tumor necrosis factor gene.          Gastroenterology 1999; 117: 1062-8.         [ Links ] 4. Satsangi J, Parkes          M, Louis E et al: Two stage genome-wide search in inflammatory          bowel disease provides evidence for susceptibility loci on chromosomes          3, 7 and 12. Nat Genet 1996; 14: 199-202.         [ Links ] 5. Ma Y, Ohmen JD, Li          Z et al: A genome-wide search identifies potential new susceptibility          loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-8.         [ Links ] 6. Brant SR, Fu Y, Fields          CT et al: American families with Crohn's disease have strong evidence          for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998;          115: 1056-61.         [ Links ] 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 3. Negoro K, Kinouchi          Y, Hiwatashi N et al: Crohn's disease is associated with novel          polymorphisms in the 5-flanking region of the tumor necrosis factor gene.          Gastroenterology 1999; 117: 1062-8.         [ Links ] 4. Satsangi J, Parkes          M, Louis E et al: Two stage genome-wide search in inflammatory          bowel disease provides evidence for susceptibility loci on chromosomes          3, 7 and 12. Nat Genet 1996; 14: 199-202.         [ Links ] 5. Ma Y, Ohmen JD, Li          Z et al: A genome-wide search identifies potential new susceptibility          loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-8.         [ Links ] 6. Brant SR, Fu Y, Fields          CT et al: American families with Crohn's disease have strong evidence          for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998;          115: 1056-61.         [ Links ] 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 4. Satsangi J, Parkes          M, Louis E et al: Two stage genome-wide search in inflammatory          bowel disease provides evidence for susceptibility loci on chromosomes          3, 7 and 12. Nat Genet 1996; 14: 199-202.         [ Links ] 5. Ma Y, Ohmen JD, Li          Z et al: A genome-wide search identifies potential new susceptibility          loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-8.         [ Links ] 6. Brant SR, Fu Y, Fields          CT et al: American families with Crohn's disease have strong evidence          for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998;          115: 1056-61.         [ Links ] 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 5. Ma Y, Ohmen JD, Li          Z et al: A genome-wide search identifies potential new susceptibility          loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-8.         [ Links ] 6. Brant SR, Fu Y, Fields          CT et al: American families with Crohn's disease have strong evidence          for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998;          115: 1056-61.         [ Links ] 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 6. Brant SR, Fu Y, Fields          CT et al: American families with Crohn's disease have strong evidence          for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998;          115: 1056-61.         [ Links ] 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 7. Rioux JD, Daly MJ,          Green T et al: Absence of linkage between inflammatory bowel disease and          selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology 1998;          115: 1062-5.         [ Links ] 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 8. Andersson RE, Olaison          G, Tysk C, Ekbom A: Appendectomy and protection against ulcerative colitis.          N Engl J Med 2001; 344: 808-14.         [ Links ] 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

 9. Evans JM, McMahon AD,          Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory          drugs are associated with emergency admission to hospital for colitis          due to inflammatory bowel disease. Gut 1997; 40: 619-22.         [ Links ]10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

10. Cosnes J, Beaugerie          L, Carbornnel F, Gendre JP: Smoking cessation and the course of Crohn's          disease: an intervention study. Gastroenterology 2001; 120: 1093-9.         [ Links ]11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

11. Lindberg E, Tysk C,          Andersson K, Jarnerot G: Smoking and inflammatory bowel disease: a case          control study. Gut 1988; 29: 352-7.         [ Links ]12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

12. Rath HC, Schultz M,          Freitag R et al: Different subsets of enteric bacteria induce and          perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69:          2277-85.         [ Links ]13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

13. Elson CO: Experimental          models of intestinal inflammatory: new insights into mechanisms of mucosal          homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock          J, McGhee JR (eds). Mucosal immunology. 2nd San Diego, California:          Academic Press 1999; 1007-24.         [ Links ]14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

14. Swidsinski A, Ladhoff          A, Pernthaler A et al: Mucosal flora in inflammatory bowel disease.          Gastroenterology 2002; 122: 44-54.         [ Links ]15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

15. Fiocchi C: Inflammatory          bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:          182-205.         [ Links ]16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

16. Sans M, Salas A, Soriano          A et al: Differential role of selectins in experimental colitis.          Gastroenterology 2001; 120: 1162-72.         [ Links ]17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

17. Koizumi M, King N,          Lobb R, Benjamin C, Podolsky  DK:          Expression of vascular adhesion molecules in inflammatory bowel disease.          Gastroenterology 1992; 103: 840-7.             [ Links ]18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

18. Saxon A, Shanahan          F, Landers C, Ganz T, Targan S: A distinct subset of antineutophil cytoplasmic          antibodies is associated with inflammatory bowel disease. J Allergy Clin          Immunol 1990; 86: 202-10.         [ Links ]19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

19. Peeters M, Joossens          S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of          anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies          in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.         [ Links ]20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

20. Vermeire S, Joossens          S, Peeters M et al: Comparative study of ASCA (anti-Saccharomyces          cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology          2001; 120: 827-3.         [ Links ]21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

21. Rigaud D, Cosnes J,          LeQuintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing          two types of enteral nutrition in treatment of active Crohn's disease:          elemental versus polymeric diet. Gut 1991; 32: 1492-7.         [ Links ]22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

22. Sutherland LR, Rothy          DE, Beck PL: Alternatives to sulfasalazine: a meta-analysis of 5-ASA in          the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-8.                  [ Links ]23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

23. Sutherland LR, Martin          F, Greer S et al: 5-aminosalicylic acid enema in the treatment          of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology          1987; 92: 1894-8.         [ Links ]24. Green JR, Lobo AJ, Holdsworth        CD et al: Balsalazide is more effective and better tolerated than        mesalamine in the treatment of acute ulcerative colitis. Gastroenterology        1998; 114: 15-22. 

25. Prantera C, Cottone          M, Pallone F et al: Mesalamine in the treatment of mild to moderate          active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology          1999; 116: 521-6.         [ Links ]26. Hannauer SB, Krawitt          EL, Robinson M, Rick GG, Safdi MA, Long-term management of Crohn's disease          with mesalamine capsules (Pentasa). Am J Gastroenterol 1993; 88: 1343-51.                  [ Links ]27. Hanauer SB, Robinson          M, Pruitt R et al: Budesonide enema for the treatment of active, distal          ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology          1998; 115: 525-32.         [ Links ]28. Mahmud N, Kamm MA,          Dupas JL et al: Olsalazine is not superior to placebo in maintaining remission          of inactive Crohn's colitis and ileocolitis: a double blind, parallel,          randomised, multicentre study. Gut 2001; 49: 552:6.         [ Links ]29. Lapinska J, Paradowski          L, Woldan J, Sozanski L, Ujec M, Lubczynska Kowalska W: Ulceratve colitis          and pregnancy. Wiad Lek 1994; 47(1-2): 53-8.         [ Links ]30. Dame WR, Karoff JC,          Wagner H: Treatment of colitis ulcerosa during pregnancy. Z Geburtshilfe          Perinatol 1979; 183(4): 307-10.         [ Links ]*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003.  

26. Hannauer SB, Krawitt          EL, Robinson M, Rick GG, Safdi MA, Long-term management of Crohn's disease          with mesalamine capsules (Pentasa). Am J Gastroenterol 1993; 88: 1343-51.                  [ Links ]27. Hanauer SB, Robinson          M, Pruitt R et al: Budesonide enema for the treatment of active, distal          ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology          1998; 115: 525-32.         [ Links ]28. Mahmud N, Kamm MA,          Dupas JL et al: Olsalazine is not superior to placebo in maintaining remission          of inactive Crohn's colitis and ileocolitis: a double blind, parallel,          randomised, multicentre study. Gut 2001; 49: 552:6.         [ Links ]29. Lapinska J, Paradowski          L, Woldan J, Sozanski L, Ujec M, Lubczynska Kowalska W: Ulceratve colitis          and pregnancy. Wiad Lek 1994; 47(1-2): 53-8.         [ Links ]30. Dame WR, Karoff JC,          Wagner H: Treatment of colitis ulcerosa during pregnancy. Z Geburtshilfe          Perinatol 1979; 183(4): 307-10.         [ Links ]*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003.  

27. Hanauer SB, Robinson          M, Pruitt R et al: Budesonide enema for the treatment of active, distal          ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology          1998; 115: 525-32.         [ Links ]28. Mahmud N, Kamm MA,          Dupas JL et al: Olsalazine is not superior to placebo in maintaining remission          of inactive Crohn's colitis and ileocolitis: a double blind, parallel,          randomised, multicentre study. Gut 2001; 49: 552:6.         [ Links ]29. Lapinska J, Paradowski          L, Woldan J, Sozanski L, Ujec M, Lubczynska Kowalska W: Ulceratve colitis          and pregnancy. Wiad Lek 1994; 47(1-2): 53-8.         [ Links ]30. Dame WR, Karoff JC,          Wagner H: Treatment of colitis ulcerosa during pregnancy. Z Geburtshilfe          Perinatol 1979; 183(4): 307-10.         [ Links ]*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003.  

28. Mahmud N, Kamm MA,          Dupas JL et al: Olsalazine is not superior to placebo in maintaining remission          of inactive Crohn's colitis and ileocolitis: a double blind, parallel,          randomised, multicentre study. Gut 2001; 49: 552:6.         [ Links ]29. Lapinska J, Paradowski          L, Woldan J, Sozanski L, Ujec M, Lubczynska Kowalska W: Ulceratve colitis          and pregnancy. Wiad Lek 1994; 47(1-2): 53-8.         [ Links ]30. Dame WR, Karoff JC,          Wagner H: Treatment of colitis ulcerosa during pregnancy. Z Geburtshilfe          Perinatol 1979; 183(4): 307-10.         [ Links ]*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003.  

29. Lapinska J, Paradowski          L, Woldan J, Sozanski L, Ujec M, Lubczynska Kowalska W: Ulceratve colitis          and pregnancy. Wiad Lek 1994; 47(1-2): 53-8.         [ Links ]30. Dame WR, Karoff JC,          Wagner H: Treatment of colitis ulcerosa during pregnancy. Z Geburtshilfe          Perinatol 1979; 183(4): 307-10.         [ Links ]*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003.  

30. Dame WR, Karoff JC,          Wagner H: Treatment of colitis ulcerosa during pregnancy. Z Geburtshilfe          Perinatol 1979; 183(4): 307-10.         [ Links ]*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003.  

*Trabajo recibido en          septiembre de 2003 y aceptado para publicación por el Comité          Editor en noviembre de 2003. 